FUTURE 2 研究 2 年结果:DAPSA、MDA 与 VLDA 在银屑病关节炎临床试验中缓解与低疾病活动状态的比较
该研究基于 FUTURE 2 试验(NCT01752634)的 2 年数据,在 secukinumab 治疗的银屑病关节炎患者中比较 DAPSA 与 MDA 复合指数定义的缓解和低疾病活动状态。结果显示更多患者可达到 DAPSA-REM 或 DAPSA-REM+LDA 而非 VLDA 或 MDA,且 DAPSA-REM+LDA 与 MDA 应答者的患者报告结局改善显著优于对照状态。
要点
- DAPSA 与 MDA 复合指数均可用于银屑病关节炎临床试验中的达标治疗评估。
- 达到 DAPSA-REM 或 VLDA 的患者在更多核心组分阈值上达标比例更高。
- DAPSA-REM+LDA 与 MDA 应答者的患者报告结局改善显著更优。
核心结论
- DAPSA 和 MDA 复合指数均可用于临床试验中银屑病关节炎患者的状态评估与治疗反应评价,并改善患者健康相关结局。
研究设计与样本
- 基于 FUTURE 2 研究(NCT01752634)的临床试验数据,对 secukinumab 治疗的银屑病关节炎患者进行 2 年观察分析。
主要发现
- 在所有时间点,总体人群中达到 DAPSA-REM 或 DAPSA-REM+LDA 的患者比例分别高于 VLDA 或 MDA 应答,且不受既往抗 TNF 使用和诊断时间影响。
- 截至第 104 周,达到 DAPSA-REM 或 VLDA 的患者在关节、疼痛、患者和医生整体评估及功能等更多核心组分阈值上达标比例高于 DAPSA-REM+LDA 或 MDA。
- 截至 104 周,MDA 较 DAPSA-REM+LDA 在患者整体评估 ≤10 mm 和 ≤20 mm 及医生整体评估 ≤10 mm 上数值上比例更高。
- 截至 104 周,VLDA 或 MDA 较 DAPSA-REM 或 DAPSA-REM+LDA 分别在患者疼痛 VAS ≤15 mm、PASI ≤1、HAQ ≤0.5 上数值上比例更高。
- DAPSA-REM+LDA 患者较 DAPSA-中高疾病活动状态患者、MDA 应答者较非应答者的患者报告结局改善显著更优。
关键数值与推荐
- DAPSA-REM 定义为 DAPSA ≤4,DAPSA-REM+LDA 定义为 DAPSA ≤14。
- VLDA 定义为达到 7/7 项标准,MDA 定义为达到 ≥5/7 项标准。
临床怎么用
- 在银屑病关节炎临床试验中可采用 DAPSA 或 MDA 复合指数进行达标治疗评估。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Remission (REM) or low disease activity (LDA) states were compared in a clinical trial setting of the FUTURE 2 study (NCT01752634) using Disease Activity Index for Psoriatic Arthritis (DAPSA) and Minimal Disease Activity (MDA) composite indices in secukinumab treated PsA patients. METHODS: The proportion of patients reaching DAPSA-REM (cut-off ≤4) or REM+LDA (≤14), and very low disease activity (VLDA; achieving 7/7 criteria) or MDA (≥5/7), were compared in the overall population, by prior use of anti-TNF therapy, and by time since diagnosis using as observed data. The proportion of patients who met individual core component and other variables of interest were also computed to assess residual disease activity in DAPSA-REM/REM+LDA states and VLDA/MDA responses. The relationship between DAPSA/MDA and patient reported outcomes (PROs), including health-related quality of life, physical function, and fatigue were assessed using mixed model for repeated measures. RESULTS: More patients could achieve DAPSA-REM or DAPSA-REM+LDA status than VLDA or MDA responses, respectively, at all the time points in the overall population, irrespective of anti‒TNF status and time since diagnosis. Higher proportion of patients reaching DAPSA-REM or VLDA achieved more thresholds of core components (joints, pain, patient and physician global assessments, and function) than DAPSA-REM+LDA or MDA over Week 104. There were differences with numerically higher proportion of patients achieving patient global assessment ≤10 mm and ≤20 mm, and physician global assessment ≤10 mm with MDA than with DAPSA-REM+LDA, and patient pain VAS ≤15 mm, PASI ≤1, HAQ ≤0.5 with VLDA or MDA than with DAPSA-REM or DAPSA-REM+LDA, respectively, through 104 weeks. Improvements in PROs were significantly better for patients in DAPSA-REM+LDA versus DAPSA-moderate+high disease activity status, and for MDA responders versus non-responders. CONCLUSION: These analysis add to the evidence that both DAPSA and MDA composite index measures can be used for evaluation of the status and treatment response utilizing a treat to target approach in PsA patients in a clinical trial setting and improve patient health related outcomes. FUNDING: The study and analysis was funded by Novartis Pharma AG, Basel, Switzerland.
引用
- Coates LC, Nash P, Kvien TK, et al. Comparison of remission and low disease activity states with DAPSA, MDA and VLDA in a clinical trial setting in psoriatic arthritis patients: 2-year results from the FUTURE 2 study. Semin Arthritis Rheum. 2020. PMID: 32521325. doi:10.1016/j.semarthrit.2020.03.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。